Provention Bio, Inc. (Nasdaq: PRVB), a US-based biopharmaceutical company, announced on Thursday that it has named Thierry Chauche as its new chief financial officer effective 1 December 2021.

The company said that Chauche has financial experience and a strong track record of success for more than two decades. He has served as the head of Strategic Financial Planning and Analysis at Alexion Pharmaceuticals. He has served in roles of increasing responsibility at Intercept Pharmaceuticals, Novartis and Rothschild & Cie.

Current CFO Andrew Drechsler will be retiring in December, following a career of nearly 30 years in the financial and life sciences industry, most notably, the past four years at Provention Bio.

Ashleigh Palmer, Provention Bio CEO & co-founder, said, 'On behalf of the board and our entire team, I would like to thank Andy for his foundational and ongoing contributions throughout these past four years as we've built Provention Bio from an idea into a company we believe is poised to change the therapeutic approach to serious autoimmune diseases from disease treatment to disease interception and prevention. Andy's strategic vision, collaborative spirit and deeply personal connection to autoimmune disease has played such a crucial role in bringing us to this point in our corporate evolution. I would also like to welcome Thierry to the Provention Bio team. His extensive commercial and strategic finance experience as well as his leadership skills are the perfect fit as we continue advancing to the next stage of our company's growth.'